References
1.
Pfaar
O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al. Guideline on
allergen-specific immunotherapy in IgE-mediated allergic diseases, S2k
Guideline of the German Society for Allergology and Clinical Immunology
(DGAKI), the Society for Pediatric Allergy and Environmental Medicine
(GPA), the Medical Association of German Allergologists (AeDA), the
Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society
for Allergy and Immunology (SGAI), the German Society of Dermatology
(DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck
Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent
Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German
Respiratory Society (DGP), the German Association of ENT Surgeons
(BV-HNO), the Professional Federation of Paediatricians and Youth
Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the
German Dermatologists Association (BVDD). Allergo J. Int.2014;23(8):282–319.
2.
Roberts
G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, van Gerth Wijk R et
al. EAACI Guidelines on Allergen Immunotherapy: Allergic
rhinoconjunctivitis. Allergy 2018;73(4):765–98.
3.
Canonica
GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S et
al. Sublingual immunotherapy: World Allergy Organization position paper
2013 update. World Allergy Organ. J. 2014;7(6):1–52.
4.
Halken
S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar Oet al. EAACI guidelines on allergen immunotherapy: Prevention of
allergy. Pediatr. Allergy Immunol. 2017;28(8):728–45.
5.
Jutel
M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W et al.International consensus on allergy immunotherapy. J. Allergy Clin.
Immunol. 2015;136(3):556–68.
6.
Frankland
AW. Preseasonal injection treatment in hay fever using aqueous extracts.Int. Arch. Allergy Immunol. 1965;28:1–11.
7.
Dhami
S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M et al.Allergen immunotherapy for allergic asthma: A systematic review and
meta-analysis. Allergy 2017;72(12):1825–48.
8.
Dhami
S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H et al. Allergen
immunotherapy for allergic rhinoconjunctivitis: A systematic review and
meta-analysis. Allergy 2017;72(11):1597–631.
9. Kim
H-S, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled
Trial: Clinical Research Based on Electronic Medical Records. J
Korean Med Sci 2018;33(34):e213.
10.
Paoletti
G, Di Bona D, Chu DK, Firinu D, Heffler E, Agache I et al.Allergen immunotherapy: The growing role of observational and randomized
trial ”Real-World Evidence”. Allergy 2021;76(9):2663–72.
11. Flynn R, Plueschke K, Quinten C, Strassmann V, Duijnhoven RG,
Gordillo-Marañon M et al. Marketing Authorization Applications
Made to the European Medicines Agency in 2018-2019: What was the
Contribution of Real-World Evidence? Clin Pharmacol Ther2022;111(1):90–7.
12.
Shamji
MH, Larson D, Eifan A, Scadding GW, Qin T, Lawson K et al.Differential induction of allergen-specific IgA responses following
timothy grass subcutaneous and sublingual immunotherapy. J.
Allergy Clin. Immunol. 2021;148(4):1061-1071.e11.
13.
Aasbjerg
K, Backer V, Lund G, Holm J, Nielsen NC, Holse M et al.Immunological comparison of allergen immunotherapy tablet treatment and
subcutaneous immunotherapy against grass allergy. Clin. Exp.
Allergy 2014;44(3):417–28.
14. Vogelberg C, Brüggenjürgen B, Richter H, Jutel M. House dust mite
immunotherapy in Germany: Real-world adherence to a subcutaneous
allergoid and a sublingual tablet. Allergo J. Int.2021;30(5):183–91.
15. Jutel M, Brüggenjürgen B, Richter H, Vogelberg C. Real-world
evidence of subcutaneous allergoid immunotherapy in house dust
mite-induced allergic rhinitis and asthma. Allergy2020;75(8):2046–54.
16.
Schmitt
J, Wüstenberg E, Küster D, Mücke V, Serup-Hansen N, Tesch F. The
moderating role of allergy immunotherapy in asthma progression: Results
of a population-based cohort study. Allergy 2020;75(3):596–602.
17.
Vogelberg
C, Brüggenjürgen B, Richter H, Jutel M. Real-World Adherence and
Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree
Pollen-Induced Allergic Rhinitis and Asthma. Patient Prefer
Adherence 2020;14:817–27.
18. Devillier P, Molimard M, Ansolabehere X, Bardoulat I, Coulombel N,
Maurel F et al. Immunotherapy with grass pollen tablets reduces
medication dispensing for allergic rhinitis and asthma: A retrospective
database study in France. Allergy 2019;74(7):1317–26.
19. Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real-world
benefits of allergen immunotherapy for birch pollen-associated allergic
rhinitis and asthma. Allergy 2019;74(3):594–604.
20.
Allam
J-P, Andreasen JN, Mette J, Serup-Hansen N, Wüstenberg EG. Comparison of
allergy immunotherapy medication persistence with a sublingual
immunotherapy tablet versus subcutaneous immunotherapy in Germany.J. Allergy Clin. Immunol. 2018;141(5):1898-1901.e5.
21. Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual
immunotherapy provides long-term relief in allergic rhinitis and reduces
the risk of asthma: A retrospective, real-world database analysis.Allergy 2018;73(1):165–77.
22. Devillier P, Wahn U, Zielen S, Heinrich J. Grass pollen sublingual
immunotherapy tablets provide long-term relief of grass
pollen-associated allergic rhinitis and reduce the risk of asthma:
Findings from a retrospective, real-world database subanalysis.Expert Rev Clin Immunol 2017;13(12):1199–206.
23.
Sieber
J, Geest S de, Shah-Hosseini K, Mösges R. Medication persistence with
long-term, specific grass pollen immunotherapy measured by prescription
renewal rates. Curr. Med. Res. Opin. 2011;27(4):855–61.
24.
Kiel
MA, Röder E, van Gerth Wijk R, Al MJ, Hop WCJ, Rutten-van Mölken MPMH.
Real-life compliance and persistence among users of subcutaneous and
sublingual allergen immunotherapy. J. Allergy Clin. Immunol.2013;132(2):353-60.e2.
25. Fritzsching B, Contoli M, Porsbjerg C, Buchs S, Larsen JR, Elliott Let al. Long-term real-world effectiveness of allergy
immunotherapy in patients with allergic rhinitis and asthma: Results
from the REACT study, a retrospective cohort study. Lancet Reg
Health Eur 2022;13:100275.
26.
Schmitt
J, Schwarz K, Stadler E, Wüstenberg EG. Allergy immunotherapy for
allergic rhinitis effectively prevents asthma: Results from a large
retrospective cohort study. J. Allergy Clin. Immunol.2015;136(6):1511–6.
27.
Oyinlola
JO, Campbell J, Kousoulis AA. Is real world evidence influencing
practice? A systematic review of CPRD research in NICE guidances.BMC Health Serv Res 2016;16:299.
28.
Saturni
S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N et
al. Randomized Controlled Trials and real life studies. Approaches and
methodologies: A clinical point of view. Pulm. Pharmacol. Ther.2014;27(2):129–38.
29.
Rawlins
M. De Testimonio: on the evidence for decisions about the use of
therapeutic interventions. Clin Med (Lond). 2008;8(6):579–588.
30.
Elliott
L, Fidler C, Ditchfield A, Stissing T. Hypoglycemia Event Rates: A
Comparison Between Real-World Data and Randomized Controlled Trial
Populations in Insulin-Treated Diabetes. Diabetes Ther2016;7(1):45–60.
31.
Ankarfeldt
MZ, Adalsteinsson E, Groenwold RH, Ali MS, Klungel OH. A systematic
literature review on the efficacy-effectiveness gap: Comparison of
randomized controlled trials and observational studies of
glucose-lowering drugs. Clin Epidemiol. 2017;9:41–51.
32.
Nordon
C, Karcher H, Groenwold RHH, Ankarfeldt MZ, Pichler F, Chevrou-Severac Het al. The ”Efficacy-Effectiveness Gap”: Historical Background
and Current Conceptualization. Value Health 2016;19(1):75–81.
33.
Katona
L, Bitter I, Czobor P. A meta-analysis of effectiveness of real-world
studies of antipsychotics in schizophrenia: Are the results consistent
with the findings of randomized controlled trials? Transl
Psychiatry 2021;11(1):510.
34.
Moran
M, Nickens D, Adcock K, Bennetts M, Desscan A, Charnley N et al.Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and
Meta-Analysis of Real-World and Clinical Trials Data. Target
Oncol 2019;14(4):405–16.
35.
Framework
for FDA’s real world evidence program [Internet]. Available from:
https://www.fda.gov/media/120060/download.
36.
Baumfeld
Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using
real-world data: The changing landscape of the regulatory approval
process. Pharmacoepidemiol Drug Saf. 2020;29(10):1201–12.
37.
Bozek
A, Cudak A, Canonica GW. Long-term efficacy of injected allergen
immunotherapy for treatment of grass pollen allergy in elderly patients
with allergic rhinitis. Allergy Asthma Proc. 2020;41:271–7.
38.
Bozek
A, Foks A, Trzaska K, Canonica GW. Long-term effects of allergen
sublingual immunotherapy. Adv Dermatol Allergol2020;37(6):943–7.
39.
Durham
SR, Emminger W, Kapp A, Monchy JGR de, Rak S, Scadding GK et al.SQ-standardized sublingual grass immunotherapy: Confirmation of disease
modification 2 years after 3 years of treatment in a randomized trial.J. Allergy Clin. Immunol. 2012;129(3):717-725.e5.
40.
Didier
A, Malling H-J, Worm M, Horak F, Sussman GL. Prolonged efficacy of the
300IR 5-grass pollen tablet up to 2 years after treatment cessation, as
measured by a recommended daily combined score. Clin. Transl.
Allergy 2015;5(12):12.
41.
Valovirta
E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HFet al. Results from the 5-year SQ grass sublingual immunotherapy
tablet asthma prevention (GAP) trial in children with grass pollen
allergy. J. Allergy Clin. Immunol. 2018;141(2):529-538.e13.
42.
Dominicus
R. 3-years’ long-term effect of subcutaneous immunotherapy (SCIT) with a
high-dose hypoallergenic 6-grass pollen preparation in adults.Allerg. Immunol. (Paris) 2012;44(3):135–40.
43.
Passalacqua
G, Bagnasco D. Real-life studies in allergen immunotherapy. Curr.
Opin. Allergy Clin. Immunol. 2021;21:361–7.
44.
Bachert
C, Larche M, Bonini S, Canonica GW, Kundig T, Larenas-Linnemann Det al. Allergen immunotherapy on the way to product-based
evaluation-a WAO statement. World Allergy Organ. J.2015;8(1):29–78.
45.
Burden
A, Roche N, Miglio C, Hillyer EV, Postma DS, Herings RM et al. An
evaluation of exact matching and propensity score methods as applied in
a comparative effectiveness study of inhaled corticosteroids in asthma.Pragmat Obs Res. 2017;8:15–30.
46.
Kuss
O, Blettner M, Börgermann J. Propensity Score - An Alternative Method of
Analyzing Treatment Effects. Dtsch Arztebl Int.2016;113(35-36):597–603.
47.
Worm
M, Rak S, Samoliński B, Antila J, Höiby A-S, Kruse B et al.Efficacy and safety of birch pollen allergoid subcutaneous
immunotherapy: A 2-year double-blind, placebo-controlled, randomized
trial plus 1-year open-label extension. Clin. Exp. Allergy2019;49(4):516–25.
48.
Zielen
S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific
immunotherapy in children with asthma: A randomized controlled trial.J. Allergy Clin. Immunol. 2010;126(5):942–9.
49.
Menditto
E, Costa E, Midão L, Bosnic-Anticevich S, Novellino E, Bialek S et
al. Adherence to treatment in allergic rhinitis using mobile
technology. The MASK Study. Clin. Exp. Allergy2019;49(4):442–60.
50. Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P,
Arnavielhe S et al. Mobile technology offers novel insights into
the control and treatment of allergic rhinitis: The MASK study. J.
Allergy Clin. Immunol. 2019;144(1):135-143.e6.
51.
Linneberg
A, Dam Petersen K, Hahn-Pedersen J, Hammerby E, Serup-Hansen N, Boxall
N. Burden of allergic respiratory disease: A systematic review.Clin Mol Allergy. 2016;14:12.
52.
Brüggenjürgen
B, Reinhold T. Cost-effectiveness of grass pollen subcutaneous
immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and
symptomatic treatment in Austria, Spain, and Switzerland. J. Med.
Econ. 2018;21(4):374–81.
53.
Green
W, Kleine-Tebbe J, Klimek L, Hahn-Pedersen J, Nørgaard Andreasen J,
Taylor M. Cost-effectiveness of SQ(®) HDM SLIT-tablet in addition to
pharmacotherapy for the treatment of house dust mite allergic rhinitis
in Germany. Clinicoecon. Outcomes Res. 2017;9:77–84.
54.
Reinhold
T, Brüggenjürgen B. Cost-effectiveness of grass pollen SCIT compared
with SLIT and symptomatic treatment. Allergo J. Int.2017;26(1):7–15.
55.
Verheggen
BG, Westerhout KY, Schreder CH, Augustin M. Health economic comparison
of SLIT allergen and SCIT allergoid immunotherapy in patients with
seasonal grass-allergic rhinoconjunctivitis in Germany. Clin.
Transl. Allergy 2015;5(1):1.
56.
Westerhout
KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis
of immunotherapy in patients with grass pollen allergic
rhinoconjunctivitis in Germany. J. Med. Econ. 2012;15(5):906–17.
57.
Keiding
H, Jørgensen KP. A cost-effectiveness analysis of immunotherapy with SQ
allergen extract for patients with seasonal allergic rhinoconjunctivitis
in selected European countries. Curr. Med. Res. Opin.2007;23(5):1113–20.
58.
Brüggenjürgen
B, Klimek L, Reinhold T. Real world effectiveness and cost consequences
of grass pollen SCIT compared with SLIT and symptomatic treatment.Allergo J Int 2021;30(6):198–206.
59. Di
Bona D, Bilancia M, Albanesi M, Caiaffa MF, Macchia L.
Cost-effectiveness of grass pollen allergen immunotherapy in adults.Allergy 2020;75(9):2319–29.
60.
Cox
LS, Murphey A, Hankin C. The Cost-Effectiveness of Allergen
Immunotherapy Compared with Pharmacotherapy for Treatment of Allergic
Rhinitis and Asthma. Immunol Allergy Clin N Am 2020;40(1):69–85.